[1. Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 32-71.10.2174/156800909787314002]Search in Google Scholar
[2. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998; 13: 893-906.10.3892/ijo.13.5.893]Search in Google Scholar
[3. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621-8.10.1016/S0955-0674(00)00141-1]Search in Google Scholar
[4. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.10.1038/nrm977]Search in Google Scholar
[5. Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des 2003; 9: 4p.10.2174/138161281030900iv]Search in Google Scholar
[6. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9: 1529-43.10.2174/1381612033454612]Search in Google Scholar
[7. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.10.1093/jnci/94.2.116]Search in Google Scholar
[8. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. for the German chemo N0 study group. Randomyzed adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.10.1093/jnci/93.12.913]Search in Google Scholar
[9. Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66.10.1007/978-0-387-79962-9_4]Search in Google Scholar
[10. Takac I, Cufer T, Gorisek B, Cas-Sikosek N, Bali R, Bosilj D, et al. [The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer]. [Slovenian]. Zdrav Vestn 2011; 80: 405-12.]Search in Google Scholar
[11. Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531-3.10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B]Search in Google Scholar
[12. Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 2: 1049.10.1016/S0140-6736(89)91070-2]Search in Google Scholar
[13. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-5.]Search in Google Scholar
[14. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648-58.10.1200/JCO.1994.12.8.1648]Search in Google Scholar
[15. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-43.]Search in Google Scholar
[16. Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. Tumori 2011; 97: 532-9.10.1177/030089161109700419]Search in Google Scholar
[17. Eljuga D, Razumovic JJ, Bulic K, Petrovecki M, Draca N, Bulic SO. Prognostic importance of PAI-1 in node negative breast cancer patients - results after 10 years of follow up. Pathol Res Pract 2011; 207: 290-4.10.1016/j.prp.2011.02.008]Search in Google Scholar
[18. Gazic B, Pizem J, Bracko M, Cufer T, Borstnar S, Pohar-Marinsek Z, et al. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients. Cytopathology 2008; 19: 294-302.10.1111/j.1365-2303.2007.00528.x]Search in Google Scholar
[19. Borstnar S, Sadikov A, Mozina B, Cufer T. High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res Treat 2010; 121: 615-24.10.1007/s10549-009-0691-8]Search in Google Scholar
[20. Xu FJ, Stack S, Boyer C, O’Briant K, Whitaker R, Mills GB, et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997; 3: 1629-34.]Search in Google Scholar
[21. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer 2000; 82: 666-74.10.1054/bjoc.1999.0979]Search in Google Scholar
[22. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998; 273: 28238-46.10.1074/jbc.273.43.28238]Search in Google Scholar
[23. Arboleda J, Slamon DJ. Heregulin induced cell invasion of HER-2/neu transfected breast cancer cell line is mediated through activation of the phosphatidylinositol 3-kinase/AKT2 pathway. Cold Spring Harbor Laboratory Meeting on Tyrosine Phosphorylation and Cell Signaling; 1999 May 12.-16. p. 11.]Search in Google Scholar
[24. Berney CR, Yang J, Fisher RJ, Russell PJ, Crowe PJ. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 1998; 10: 47-54.]Search in Google Scholar
[25. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-9.10.1200/JCO.2000.18.11.2201]Search in Google Scholar
[26. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-66.10.1016/S0065-230X(08)60028-7]Search in Google Scholar
[27. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemostasis 1997; 78: 285-96.10.1055/s-0038-1657541]Search in Google Scholar
[28. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-8.10.1200/JCO.2003.04.17012637466]Search in Google Scholar
[29. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, et al. HER2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7: 2448-57.]Search in Google Scholar
[30. Decker T, Hungermann D, Böcker W. [Prognostic and predictive factors of invasive breast cancer: update 2009]. [German]. Pathologe 2009; 30: 49-55.10.1007/s00292-008-1105-019184022]Search in Google Scholar
[31. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone; 1987. p. 300-11.]Search in Google Scholar
[32. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up. Br J Cancer 1999; 80: 419-26.10.1038/sj.bjc.6690373236231310408848]Search in Google Scholar
[33. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997; 76: 306-11.10.1038/bjc.1997.38322240719252196]Search in Google Scholar
[34. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54: 147-57.10.1023/A:1006118828278]Search in Google Scholar
[35. Cufer T, Vrhovec I, Borštnar S. Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival. Int J Biol Mark 2002; 17: 33-41.10.1177/172460080201700104]Search in Google Scholar
[36. Cufer T, Vrhovec I, Borštnar S. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 and PAI-2 in operable breast cancer. Int J Biol Mark 2003; 18: 106-15.10.1177/172460080301800203]Search in Google Scholar
[37. Cufer T. Clinical utility of serine proteases in breast cancer. Radiol Oncol 2004; 38: 85-92.]Search in Google Scholar
[38. Ferrero-Poüs M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000; 6: 4745-54.]Search in Google Scholar
[39. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, et al. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer 2008; 4: 168-77.10.3816/CBC.2008.n.01818621614]Search in Google Scholar
[40. Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.10.1200/JCO.2002.20.4.100011844823]Search in Google Scholar
[41. Esteva FJ, Hortobagyi GN. Prognostic markers in early breast cancer. Breast Cancer Res 2004; 6: 109-18.10.1186/bcr77740067415084231]Search in Google Scholar
[42. De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, et al. Breast Cancer Study Group of the Institut Curie. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 2009; 29: 1475-82.]Search in Google Scholar
[43. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. J Natl Cancer Inst 2006; 98: 262-72.10.1093/jnci/djj05216478745]Search in Google Scholar